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Primary balloon angioplasty plus balloon
angioplasty maturation to upgrade small-caliber
veins (3 mm) for arteriovenous fistulas
Lorena P. De Marco Garcia, MD, Luis R. Davila-Santini, MD, Qin Feng, MD, Julio Calderin, MD,
Kambhampaty V. Krishnasastry, MD, and Thomas F. Panetta, MD, Manhasset, NY
Objective: Small-diameter veins are often a limiting factor for the successful creation of arteriovenous fistulas (AVFs). This
study evaluated the use of intraoperative primary balloon angioplasty (PBA) as a technique to upgrade small-diameter
veins during AVF creation. Sequential balloon angioplasty maturation (BAM) was evaluated as a technique to salvage
failed fistulas, expedite maturation, and improve the patency of AVFs after PBA.
Methods: Sixty-two PBAs were performed in 55 patients with an intent-to-treat using an all-autologous policy. PBAs of
veins were performed just before AVF creation using 2.5- to 4-mm angioplasty balloons (1- to 1.5-mm larger than the
nominal vein diameter). PBAs were performed through the spatulated end of the vein for a length of up to 8 cm using
hydrophilic guidewires and hand inflations without fluoroscopy. BAM was performed in 53 of the 62 PBAs at 2, 4, and
6 weeks after the PBA. Successful outcome was determined as the functional ability to use the fistula for hemodialysis
without surgical revision.
Results: Of the 62 PBAs, 53 (85.4%), comprising 47 of the original AVFs and 6 new site AVFs created at other sites,
remained patent and subsequently underwent BAMwith a resulting functional AVF. Fifteen of the 47 original AVFs: 14
due to occlusion; one AVF with a steal was ligated. Seven of the 14 fistulas that occluded were salvaged using
recanalization techniques during sequential BAMs. Two of the seven fistulas that were not salvaged required AVGs (3%),
and five patients underwent redo AVFs using alternative veins. These five cases were also performed using PBAs and
BAMs technique. One patient with a functioning fistula underwent intentional ligation for steal syndrome and also
underwent an alternative site AVF, PBA, and BAM. At 3 months, 53 AVFs were functional and successfully used for
dialysis. Overall, a working AVF was obtained at the initial site in 47 of 55 patients (85.4%), and 53 (96.3%) received
working AVFs that were functioning for dialysis access.
Conclusions: Small or suboptimal veins can undergo PBA and then be matured to create functioning AVFs <2 months.
Overall,>90% autogenous AVF rates can be achieved using PBA and BAM. BAM can be successfully used tomature AVFs
created from small veins and salvage thrombosed AVFs in many cases. The use of these techniques may decrease the
number of patients requiring AVGs and indwelling catheters. ( J Vasc Surg 2010;52:139-44.)An arteriovenous fistula (AVF) is the procedure of
choice for primary and secondary hemodialysis access.1
AVFs have a reduced infection rate and cost compared with
grafts and indwelling catheters and also have increased
overall patency and improved patient survival.2-8 At the
beginning of 2003, an AVF was the primary vascular access
in 32.4% of patients in the United States who required
hemodialysis. By May 2009, this percentage had increased
to 52.6%.9 This improvement did not meet the expecta-
tions of the Kidney Disease Outcomes Quality Initiative
(NKF-DOQI 2001), which recommended 66% of renal
failure patients should undergo AVF creation by 2009.
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doi:10.1016/j.jvs.2010.02.013Numerous techniques have been used to improve fis-
tula function, including venous and arterial angioplasty,
stent placement, thrombectomy, venous branch ligation,
fistula superficialization, banding, interposition vein grafts,
transposition, and extensive preoperative imaging.10-13
Despite these techniques, fistula rates remain low because
these interventions maintain function but do not specifi-
cally address the issue of increasing vein utilization.
In an effort to increase the number of primary AVFs,
shorten maturation times, and reduce the number of in-
dwelling catheters, we have developed two new techniques
in conjunction with an overall strategy designed to create
and expedite the use of a functioning AVF. These include
primary balloon angioplasty (PBA) during fistula creation
in selected patients with small veins, combined with bal-
loon angioplasty maturation (BAM)14 of all AVFs. Surveil-
lance programs with preemptive reintervention have also
been instituted.
METHODS
During the period of July 2006 to December 2008, 55
patients (24 women, 31 men) underwent PBAs using an
intent-to-treat all-autologous policy. The patients were a
mean age of 65.5 years (range, 48-84 years). Of these, 16
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AVF was the first hemodialysis access, and 39 patients were
receiving hemodialysis and had at least one prior AVF/
AVG (multiples in 5 patients). Previous ipsilateral access
was present in 23 patients.
Sixty-two procedures were performed: 39 Brescia-
Cimino type, 15middle forearm radiocephalic, 7 antecubital/
cephalic veins, and 1 accessory (posterior vein to radial artery)
fistula were created. All were cephalic vein, and no basilic vein
fistulas were included in the study. All patients with subopti-
mal veins undergoing AVF creation were ballooned up 1- to
1.5-mm larger than the nominal vein diameter. Veins3mm
were excluded from the study (Table I).
A thorough preoperative evaluation was performed in
the 55 patients receiving surgical access. Physical examina-
tion included upper arm inspection with and without tour-
niquet placement to determine site preference. The non-
dominant upper extremity was favored when feasible.
Preoperative vein mapping was used in all cases.15 Veins
3.0 mm in diameter (measured by ultrasound with a
tourniquet, outer wall-to-outer wall) were considered sub-
optimal. Intraoperative diameters were measured with a
combination of calipers and Garrett dilators in all patients
who underwent PBA before AVF creation. The study did
not include patients with veins 3 mm in diameter. Mea-
surements were confirmed by venography on the first BAM
performed in all patients who had documented veins 3
mm based on dilation with an initial 3-mm balloon to
nominal pressure.
PBA was performed through the spatulated end of the
venotomy over an angled 0.035-inch hydrophilic wire
(0.014-inch for 2.5-mm balloons). Veins with diameters
between 1 and 3 mm underwent balloon angioplasty 1- to
1.5-mm larger than the nominal vein diameter from the
middle forearm to the spatulated end of the vein. Spatu-
lated veins were initially hydrostatically dilated with a 21-
gauge angiocatheter before measurement. All veins did not
allow passage of a 5F pediatric feeding tube before balloon
angioplasty.
Angioplasty balloons ranged from 2.5 mm (2-cm long)
to 4 mm (2- to 4-cm long) in size and were inflated under
direct visualization and palpation. The inflation pressure
required to dilate the veins ranged from 4 to 8 atm. The
length of the angioplasty ranged from 4 to 12 cm as
measured by balloon length. This required two to three
overlapping angioplasties per vein beginning in the mid-
Table I. Vein characteristics
Patients, No. Vein diameter, mm
20 3
8 2.5
26 2
5 1.5
3 1
62forearm and progressing toward the spatulated end of thevein. For the final angioplasty, 5 mm of the balloon tra-
versed the spatulated end of the vein and protruded out to
ensure complete dilatation.
Before the anastomosis was performed, veins were irri-
gated with a 5F pediatric feeding tube to hydrostatically
dilate the transition between the angioplastied and nonan-
gioplastied vein. The end-to-side anastomosis of the AVF
was created after the angioplasty (Figs 1 and 2). Fluoros-
copy was not necessary for these procedures.
Of the 62 PBA procedures, 53 patients underwent
subsequent BAMs on weeks 2, 4, and 6 to aid inmaturation
of the usable portion of the AVF. Eight patients, compris-
ing seven occlusions that could not be recanalized and one
with steal, did not undergo BAMs. Initial BAMs were
performed under radiologic guidance with a retrograde
radial arterial approach using a 0.018-inch platform at week
2 and an antegrade proximal fistula approach on a 0.035-
Fig 1. Balloon placement over 0.35-inch angled wire.
Fig 2. Vein after anastomosis.inch platform at weeks 4 and 6.
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performed 2 to 3 mm larger than the measured vein diam-
eter at each session. Ballooning was performed using an
inflation device with an average pressure of 12 atm. The
venous side of the anastomosis, which had undergone PBA,
was routinely angioplastied to 3 to 4mm at the initial BAM.
The length of the AVF used for access (venipuncture) was
sequentially dilated to an average diameter of 8 mm for
forearm AVFs and to 12 to 16 mm for upper arm AVFs.
Sites of extravasation were limited and controlled dur-
ing the angioplasty. Success was determined as the ability to
use the fistula for hemodialysis without revision for 90 days.
All fistulas were used 2 weeks of the final BAM.
All patients underwent routine clinical surveillance and
radiologic evaluation, when indicated, in an attempt to
prevent late failure of the AVF. Angiography was per-
formed based on evidence of venous hypertension, de-
creased flow rates at hemodialysis (250 mL/min), dimin-
ished or absent thrill at the fistula, and prophylactically at 3-
to 6-month intervals as determined by clinical indications.
RESULTS
The major component of this PBA patient population
comprised native, sclerotic, small-diameter tortuous vein
segments. In two patients with totally occluded sclerotic
veins, glidewire cannulation and PBA were performed,
resulting in functional fistulas (Fig 3).
Of the 62 PBA procedures, 53 (85.4%) remained
patent and subsequently underwent BAM with a resulting
Fig 3. Totally occluded vein at the time of original primary
balloon angioplasty recanalized undergoing balloon angioplasty
maturation.functional AVF. These consisted of 47 of the original AVFsand 6 new AVFs created at other sites. Occlusions occurred
in 14 of the 55 fistulas (25.5%), and 7 were salvaged using
BAM techniques. The mean balloon diameter for all dila-
tations was 3.5 mm. Of the initial 55 AVFs placed, 47
(85.4%) were made functional and 15 failed, 14 due to
occlusion. Seven were salvaged using recanalization tech-
niques and sequential BAM. Of the remaining eight pa-
tients, five were unsalvaged and received AVFs at another
site using PBA and BAM techniques and two required graft
placement. One AVF had to be ligated secondary to steal
syndrome with successful creation of AVF in another site
using PBA and BAM techniques as well.
Overall, 47 of 55 patients (85.4%) obtained a working
AVF at the initial site, and 53 (96.3%) received working
AVFs. All fistulas were functioning at 90 days after the final
BAM. The duration of use of each fistula for hemodialysis is
shown on the Kaplan-Meier curve and table analysis (Fig 4,
Table II). Graft placement was necessary in only 2 of the 55
patients (3.6%) who had intraoperative PBA, followed by
BAM.
Fistulograms during maturation demonstrated healing
signs such as lack of contrast extravasation and smooth wall
lining in all veins at both the PBA site and the entire length
of the usable segments of fistulas subjected to sequential
balloon maturations. PBA sites that were salvaged after
occlusion (7 cases) and ballooned to a 4-mm diameter at
the initial maturation maintained patency and demon-
strated angiographic features of healing.
DISCUSSION
The use of small-caliber veins for AVF creation is an
important—but not the only—step to achieve the recom-
mended NKF-DOQI guidelines. Previous research has
shown that the use of small-diameter veins for access is
directly related to the number of revisions and complica-
tions.16,17 Using smaller veins for AVFs has resulted in an
increased number of fistula revisions and an increased num-
ber of nonmatured fistulas.18 Allon and Robbin19 reported
veins 2.5 mm in diameter to have poor outcomes, and
recommendations for not using smaller-diameter veins
have been established. We are extending the statement to
the 3-mm veins in our study group since wemeasured them
in a wall-to-wall fashion.
In our experience with these two new techniques, PBA
and subsequent BAM improve the results with suboptimal
veins 3 mm in diameter. Prior techniques using hydro-
static dilation in addition to the administration of local
vasodilators have not been successful with these small-
diameter veins.20 In our practice, the use of mechanical or
hydrostatic dilatation often fails in fibrotic veins of such
small caliber. We commonly encounter difficulty in placing
pediatric feeding tubes (5F to 8F) for hydrostatic dilation in
veins 2 mm. In the same way, cannulation and advance-
ment of a Garret dilator is often challenging, repeatedly
resulting in vein perforation. Increased shear trauma and
countertraction tears can also occur when trying to me-
chanically dilate unforgiving vein segments. Hydrodilation
demonstrates less effective radial force and may not gener-
paten
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veins.
Glidewire access to the venous conduit when PBA is
used allows for easy balloon access, and sufficient force is
generated through angioplasty to dilate small-diameter
sclerotic vein segments. With PBA, the veins (4 to 6 cm
from the anastomosis) then undergo intraoperative angio-
plasty with 2.5- to 4-mm-diameter balloons before the
end-to-side anastomosis is performed. These veins are
clearly injured, but balloon dilatation facilitates performing
the anastomosis and subsequent maturation. Glidewire
cannulation during BAM is also facilitated. Glidewire re-
canalization was feasible even in the occluded segments (7
cases in this study) due to the larger-diameter vein at the
original PBA. These PBA segments angioplastied to a di-
ameter of 3 to 4 mm provide an adequate inflow to the
AVF.
For forearm AVFs, the inflow of the fistula (which
corresponds to the PBA segment) is not made larger than 4
mm and transitions to an 8- to 10-mm-diameter fistula in
the area used for cannulation. The inflow for upper arm
AVFs is also kept at 4 mm while transitioning to a 12- to
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Fig 4. Kaplan-Meier curve shows cumulative secondary16-mm area for cannulation. We believe this morphologyreduces the incidence and/or severity of steal. Only one
patient with severe small vessel disease in the palmar arch
and digital vessels required ligation of the AVF secondary
to severe steal. The PBA allows enough inflow to maintain
patency of veins. BAM to large-diameter AVFs has reduced
the need for superficialization of these fistulas and has
avoided the use of basilic vein transpositions in our experi-
ence.
Arterialization of PBA and BAM segments heal mostly
by fibrosis, and we postulate that these AVFs eventually
become large-diameter fibrous segments. These fibrous
AVFs have not demonstrated a propensity for aneurysmal
degeneration. Healing of these segments is further sup-
ported by the appearance of these fistulas during the se-
quential fistulograms obtained during BAMs. Evidence of
mild extravasation is shown to heal with a smooth lining on
subsequent images. We have found that 2-week intervals
provide an optimal time for healing between angioplasty,
and no vein ruptures occurred during any of the PBA and
BAM procedures.
The process of focal angioplasty injury to the venous
endothelium and subsequent healing process seen after
t Risk S.E. 
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duits contribute more to improved patency than the overall
characteristics of the fistula wall, which are yet to be deter-
mined.
CONCLUSION
The use of intraoperative PBA and subsequent BAM
allows the creation of AVF with suboptimal veins that
otherwise would not have been used. Small and tortuous
veins can still be matured to achieve an autogenous AVF
rate 96%. Secondary procedures can then allow for com-
plete maturation of small diameter, sclerotic, tortuous vein
segments previously unsuitable for successful AVF creation.
Immature AVFs require sequential BAM for maturation
and patency improvement. The use of these techniques
decreases the number of patients who require AVGs and
indwelling catheters.
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